

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Hygeia Healthcare Holdings Co., Limited**

**海吉亚医疗控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6078)**

### **VOLUNTARY ANNOUNCEMENT**

#### **KEY OPERATING DATA FOR THE FIVE MONTHS ENDED MAY 31, 2026**

This announcement is made by Hygeia Healthcare Holdings Co., Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis, to keep the shareholders and potential investors of the Company informed of the latest business developments of the Group.

For the five months ended May 31, 2026, the number of the Group’s out-patient visits was approximately 1,453,000, representing an increase of 4.0% as compared with the corresponding period in 2025, and the number of surgeries completed by the Group was approximately 38,000, representing an increase of 7.6% as compared with the corresponding period in 2025, with level 3 and 4 surgeries amounting to approximately 18,000, representing an increase of 15.2% as compared with the corresponding period in 2025. In addition, since the second half of last year, the Group’s international medical services have shown strong growth momentum, with several of its hospitals successively expanding their international medical services, the geographic coverage of international patients continuing to grow, and the number of patients treated steadily increasing. Three floors of international medical wards have been brought into operation.

The market demand for medical services is stable and sustainable. The Group has maintained robust operations, and has focused on the treatment of cancer and emergency and critical care while continuously consolidating its brand reputation. It has actively expanded its range of high-technical diagnostic and treatment services, including level 3 and 4 surgeries, interventional surgeries and endoscopic surgeries, while continuously enriching its portfolio of diagnostic and treatment services such as commercial insurance, consumer medical services and international medical services, with the proportion of revenue from self-paid services steadily increasing.

Since the beginning of this year, the efficiency of medical insurance settlements has continued to improve. The proportion of the Group's revenue from medical insurance has gradually decreased, while the cash flow has remained strong. As the interest-bearing liabilities have further declined compared with the beginning of this year and capital expenditure has steadily decreased, the Group's free cash flow is expected to be further bolstered. The Group will continue to enhance shareholder returns and implement capital allocation aligned with long-term shareholder value.

The information contained herein is based on a preliminary assessment of the Group and the information currently available to the Company and is not based on any figure or information which has been audited or reviewed by the auditor of the Company. The above figures contained in this announcement are for illustrative purposes only, and do not constitute forward-looking statements or profit numbers.

**Shareholders and potential investors of the Company are advised not to place undue reliance on the information contained in this announcement and should exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Hygeia Healthcare Holdings Co., Limited**  
**Mr. Zhu Yiwen**  
*Chairman*

Hong Kong, June 17, 2026

*As of the date of this announcement, the board of directors of the Company comprises Mr. Zhu Yiwen as chairman and executive director, Mr. Ren Ai, Ms. Cheng Huanhuan, Mr. Zhang Wenshan and Ms. Jiang Hui as executive directors, and Mr. Ye Changqing, Mr. Zhao Chun and Mr. Zhang Guozhong as independent non-executive directors.*